Literature DB >> 11990867

Prospective study of multiple sclerosis with early onset.

A Ghezzi1, C Pozzilli, M Liguori, M G Marrosu, N Milani, C Milanese, I Simone, M Zaffaroni.   

Abstract

Fifty-four subjects (36 females and 18 males) affected by clinically definite multiple sclerosis (MS) and with onset of the disease at 15 years of age or before were prospectively studied in five Italian MS centres. Female/male ratio was 4.7 in subjects with age > or = 12 years, suggesting a role of hormonal changes in triggering MS onset The mean follow-up duration was 10.9+/-5.6 years. The functional systems more frequently involved at onset were the pyramidal and brainstem (both in 28% of cases). The onset was monosymptomatic in 31 subjects (57%). The course was relapsing-remitting in 39 subjects (72%) and relapsing-progressive in 15 (28%). Disability was assessed by the Expanded Disability Status Scale (EDSS): the mean score after 8 years of follow up was 3.5 (+/-2.5). The score was <4 in 68% of cases, between 4 and 6 in 8% of cases, >6 in 24% of cases. Disability after 8 years was highly predicted by disability in the first year (p=0.008). There was a tendency to a worse prognosis in relation to the number of relapses in the first 2 years (p=0.08). The outcome was not influenced by the characteristics of symptoms at onset age and gender.

Entities:  

Mesh:

Year:  2002        PMID: 11990867     DOI: 10.1191/1352458502ms786oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  28 in total

1.  The course of early-onset multiple sclerosis in Iraqi children.

Authors:  Hasan A Al-Hamadani; Atheer S Abdalla; Atheer J Al-Saffar
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

2.  Clinical characteristics and long term prognosis in early onset multiple sclerosis.

Authors:  Olivier Deryck; Pierre Ketelaer; Bénédicte Dubois
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

3.  Paediatric multiple sclerosis and acute disseminated encephalomyelitis in Germany: results of a nationwide survey.

Authors:  Daniela Pohl; Isabell Hennemuth; Rüdiger von Kries; Folker Hanefeld
Journal:  Eur J Pediatr       Date:  2007-01-12       Impact factor: 3.183

4.  Mitochondrial DNA haplogroups and mutations in children with acquired central demyelination.

Authors:  S Venkateswaran; K Zheng; M Sacchetti; D Gagne; D L Arnold; A D Sadovnick; S W Scherer; B Banwell; A Bar-Or; D K Simon
Journal:  Neurology       Date:  2011-02-02       Impact factor: 9.910

5.  Characteristics of Children and Adolescents With Multiple Sclerosis.

Authors:  Anita L Belman; Lauren B Krupp; Cody S Olsen; John W Rose; Greg Aaen; Leslie Benson; Tanuja Chitnis; Mark Gorman; Jennifer Graves; Yolander Harris; Tim Lotze; Jayne Ness; Moses Rodriguez; Jan-Mendelt Tillema; Emmanuelle Waubant; Bianca Weinstock-Guttman; T Charles Casper
Journal:  Pediatrics       Date:  2016-07       Impact factor: 7.124

Review 6.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

Review 7.  Pediatric multiple sclerosis.

Authors:  E Ann Yeh; Tanuja Chitnis; Lauren Krupp; Jayne Ness; Dorothée Chabas; Nancy Kuntz; Emmanuelle Waubant
Journal:  Nat Rev Neurol       Date:  2009-10-13       Impact factor: 42.937

Review 8.  Therapies for multiple sclerosis: considerations in the pediatric patient.

Authors:  Brenda Banwell; Amit Bar-Or; Gavin Giovannoni; Russell C Dale; Marc Tardieu
Journal:  Nat Rev Neurol       Date:  2011-01-11       Impact factor: 42.937

9.  Pediatric multiple sclerosis.

Authors:  Yashma Patel; Vikram Bhise; Lauren Krupp
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

Review 10.  Disease-modifying therapy of pediatric multiple sclerosis.

Authors:  Tanuja Chitnis
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.